Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B
28 mars 2023 08h00 HE
|
Vaccitech plc
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpointsVTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen...
Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
20 mars 2023 08h00 HE
|
Vaccitech plc
VTP-200 was generally well-tolerated with no product-related serious adverse events (SAEs)Interim data showed encouraging initial immunogenicity results, particularly in relation to the E1, E2 and E6...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
27 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Advanced HPV16 Positive Head and Neck Cancer
15 déc. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 15, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
27 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference
25 oct. 2022 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
CORRECTION -- OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test
12 juil. 2022 14h55 HE
|
OmniPathology
PASADENA, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by OmniPathology, please note that the second sentence in paragraph one should read "The...
OmniPathology Announces the Launch of its Oropharyngeal HPV PCR Test
12 juil. 2022 08h45 HE
|
OmniPathology
PASADENA, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- OmniPathology, an independent, physician-owned and operated pathology lab, today announced the launch of a new oral test for human papillomavirus...
HPV Vaccine Market: 5.73B by 2028, Human Papillomavirus Vaccine Market Growing at 5% CAGR Lead by 9-Valent HPV Vaccine Segment, Global Analysis by The Insight Partners
17 juin 2022 08h26 HE
|
The Insight Partners
New York, June 17, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Human Papillomavirus (HPV) Vaccine Market Size, Share, Growth, Revenue, Trends, Forecast to 2028...
Baum Hedlund Issues Guide for Gardasil Injury Victims
10 juin 2022 12h07 HE
|
Baum Hedlund Aristei & Goldman
Los Angeles, California, June 10, 2022 (GLOBE NEWSWIRE) -- Personal injury lawyers from the Baum Hedlund law firm have released a new Gardasil Injury Compensation Guide to help victims who allege...